In a recent randomized placebo-controlled trial of patients admitted for COVID-19 infection, the administration of dapagliflozin showed a trend to multiorgan protection, including AKI.
← all excerpts
New Insights Into Diuretic Use to Treat Congestion in the ICU: Beyond Furosemide.
1
—
—